Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation by Martins-de-Souza, Daniel et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Psychiatry
Open Access Research article
Proteome analysis of schizophrenia patients Wernicke's area 
reveals an energy metabolism dysregulation
Daniel Martins-de-Souza*1,2,3, Wagner F Gattaz1, Andrea Schmitt4, 
José C Novello2, Sérgio Marangoni2, Christoph W Turck3 and 
Emmanuel Dias-Neto1,5
Address: 1Laboratório de Neurociências, Instituto de Psiquiatria, Faculdade de Medicina da USP, Rua Dr. Ovídio Pires de Campos, no 785, São 
Paulo, SP, CEP 05403-010, Brazil, 2Max Planck Institute of Psychiatry, Kraepelinstrasse 2, D-80804, Munich, Germany, 3Departamento de 
Bioquímica, Instituto de Biologia, UNICAMP, CEP 13083-970, Campinas, SP, Brazil, 4Department of Psychiatry, Von Siebold Str. 5, University of 
Goettingen, 37075 Goettingen, Germany and 5University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, 
USA
Email: Daniel Martins-de-Souza* - martins@mpipsykl.mpg.de; Wagner F Gattaz - gattaz@usp.br; Andrea Schmitt - aschmit@gwdg.de; 
José C Novello - jcn@unicamp.br; Sérgio Marangoni - marango@unicamp.br; Christoph W Turck - turck@mpipsykl.mpg.de; Emmanuel Dias-
Neto - emmanuel@usp.br
* Corresponding author    
Abstract
Background: Schizophrenia is likely to be a consequence of DNA alterations that, together with
environmental factors, will lead to protein expression differences and the ultimate establishment
of the illness. The superior temporal gyrus is implicated in schizophrenia and executes functions
such as the processing of speech, language skills and sound processing.
Methods: We performed an individual comparative proteome analysis using two-dimensional gel
electrophoresis of 9 schizophrenia and 6 healthy control patients' left posterior superior temporal
gyrus (Wernicke's area – BA22p) identifying by mass spectrometry several protein expression
alterations that could be related to the disease.
Results: Our analysis revealed 11 downregulated and 14 upregulated proteins, most of them
related to energy metabolism. Whereas many of the identified proteins have been previously
implicated in schizophrenia, such as fructose-bisphosphate aldolase C, creatine kinase and neuron-
specific enolase, new putative disease markers were also identified such as dihydrolipoyl
dehydrogenase, tropomyosin 3, breast cancer metastasis-suppressor 1, heterogeneous nuclear
ribonucleoproteins C1/C2 and phosphate carrier protein, mitochondrial precursor. Besides, the
differential expression of peroxiredoxin 6 (PRDX6) and glial fibrillary acidic protein (GFAP) were
confirmed by western blot in schizophrenia prefrontal cortex.
Conclusion: Our data supports a dysregulation of energy metabolism in schizophrenia as well as
suggests new markers that may contribute to a better understanding of this complex disease.
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Background
Several studies using global gene expression and proteom-
ics analyses in different brain regions of schizophrenia
(SCZ) patients have revealed dysfunctions in synaptogen-
esis and neural plasticity, energy metabolism, cytoskele-
ton assembly and oligodendrocyte metabolism [1-13].
One of the main clinical features in SCZ is the inappropri-
ate use of language such as preservations, low verbal flu-
ency, or absent-mindedness with use of incoherent
language. They can be assumed under formal thought dis-
orders and represent reliable diagnostic criteria for schiz-
ophrenia. As a complex and dynamic cognitive system
that integrates multiple levels of linguistic and cognitive
processing, language can be distinguished in micro- and
macrolinguistic dimensions that are compromised in SCZ
[reviewed in [14]]. The superior temporal gyrus (STG),
which is part of the human temporal lobe, is the major
brain area related to speech, language and communica-
tion. Injuries such as tumors, stroke or epilepsy affecting
the STG may lead to disturbances of language function
and hallucinations similar to those observed in SCZ
symptoms [15]. The left STG (L-STG) gray matter was
shown altered compared to the right STG as well as the
brain symmetry in SCZ patients [16-19]. Interestingly, the
volume of the L-STG cortex was negatively correlated with
deficit symptoms [18] and was shown to be decreased to
a larger extent in patients with poor-outcome compared
to those with good outcomes [20]. Binding sites of the
glutamatergic N-methyl-D-aspartic acid (NMDA) receptor
have been reported to be increased in the STG to a greater
extent on the left side in patients with predominantly neg-
ative symptoms [21,22]. The L-STG, specialized in lan-
guage skills, is formed by the primary auditory cortex
(Brodmann's Areas (BA) 41 and 42) and the Wernicke's
area (WA), also described as the posterior region of BA22.
WA is an important region for speech processing and lan-
guage skills.
We performed comparative individual proteomic analyses
of L-STG (WA or BA22p) tissues of 9 SCZ patients and 6
controls, using two-dimensional gel electrophoresis (2-
DE), followed by MALDI-TOF/TOF (Matrix-Assisted Laser
Desorption/Ionization/Time of Flight) mass spectrome-
try. The 25 regulated proteins identified here include
novel as well as previously reported putative SCZ markers
that may be involved in disease pathobiology.
Methods
Human Wernicke's area (WA)
Post-mortem  brain samples from the left WA tissue
(BA22p) were collected from 9 schizophrenia patients
and 6 controls. Control subjects were free from psychiatry
disorders, somatic diseases or brain tumors and had never
been treated with antidepressant or antipsychotic medica-
tions. Brain samples were dissected by an experienced
neuropathologist (median: 20.5 hours (min.7 hours –
max.37 hours) after death) and deep-frozen immediately
after collection.
All samples were obtained from the brain bank of the
Central Institute of Mental Health (Mannheim, Ger-
many). Controls were collected at the Institute of Neu-
ropathology, Heidelberg University, and clinical records
were collected from relatives and general practitioners.
Patient samples were derived from in-patients of the Men-
tal State Hospital Wiesloch, Germany. All cases and con-
trols were German whites. All SCZ patients were long-
term in-patients at the Mental State Hospital Wiesloch,
Germany, and SCZ diagnosis was made ante-mortem by an
experienced psychiatrist according to the DSM-IV criteria
[23]. For each patient the antipsychotic treatment history
was assessed by examining the medical charts and calcu-
lated in chlorpromazine equivalents (CPE), through the
algorithm developed by Jahn and Mussgay [24] for typical
neuroleptics and clozapine. The CPE of olanzapine was
calculated using the mean doses described by Meltzer and
Fatemi [25]. All patients and controls underwent neu-
ropathologic characterization to rule out associated neu-
rovascular or neurodegenerative disorders. The
classification according to Braak was stage II or less for all
subjects [26,27]. Patients and controls had no history of
alcohol or drug abuse and severe physical illness. All
assessments and post-mortem evaluations and procedures
were previously approved by the ethics committee of the
Faculty of Medicine of Heidelberg University, Germany.
Detailed patient information is given in Additional file 1.
Sample Preparation
Fifty milligrams of human WA were individually homog-
enized in 1.5 ml tubes with glass spheres in 200 μl of 7 M
urea, 2 M thiourea, 4% CHAPS, 2% ASB-14 and 70 mM
DTT buffer [28]. Samples were centrifuged for 10 min at
14,000 rpm and quantified [29]. Supernatants were used
for 2-DE.
Two-Dimensional Gel Electrophoresis
Using two-dimensional gel electrophoresis we performed
an individual proteome analysis of 9 schizophrenia sam-
ples compared to a pool of 6 healthy control. The experi-
ments were carried out as described by Martins-de-Souza
et al. [28]. Briefly, 650 μg of protein from SCZ or control
samples were applied to IPG gel strips with a nonlinear
separation range of pH 3–10 prior the second dimension
in 12.5% T acrylamide gels that were stained using a col-
loidal coomassie blue protocol.
All experiments were performed in triplicate. Only pro-
teins that appeared to be differentially expressed in tripli-
cate gels were considered as differentially regulated.BMC Psychiatry 2009, 9:17 http://www.biomedcentral.com/1471-244X/9/17
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Determination of protein expression differences and 
protein identification by peptide mass fingerprinting
2-DE gel images were used for spot detection and pI/MW
calibration of WA samples using the ImageMaster 2D soft-
ware, (GE Healthcare, Uppsala, Sweden). A total of thirty
2-DE profiles were analyzed, consisting of 27 gels from
patients (9 patients evaluated individually in triplicates)
plus three gels for the controls (triplicates of pooled con-
trols). Volumes of all spots in SCZ and CTRL gels were
determined and corresponding spots were matched for all
2-DE profiles. The spot volumes were analyzed by
Kruskal-Wallis one-way analysis of variance aiming to
reveal the statistically significant differences in the protein
expression between the two groups. Protein spots with a
mean n-fold change between SCZ and CTRL WA gels of +/
- 1.8 were excised for mass spectrometry (MS) identifica-
tion. False discovery rate (FDR) was calculated according
to Storey, 2002 [30]http://www.genomine.org/qvalue/
index.html. Protein identification by peptide mass finger-
printing was done as described by Martins-de-Souza et al.
[31].
Western Blot
For western blot analysis, proteins were extracted as
described above. One-hundred μg of total protein from
dorsolateral prefrontal cortex (DLPFC) were run on a 12%
SDS minigel (Bio-Rad, Hercules, CA, USA) and the pro-
teins were transferred to Immobilon PVDF membranes
(Millipore, Bedford, MA) at 100 V for 1 h with cooling.
Membranes were treated with 5% Carnation instant non-
fat dry milk in TBS-T for 4 hours, rinsed in TBS-T 3 times
for 20 minutes and incubated with anti-PRDX6 (Abcam,
Cambridge, UK) or anti-GFAP antibodies (Abcam, Cam-
bridge, UK) at a 1:1000 dilution in TBS-T overnight at
4°C. In the next day, membranes were washed with water
and TBS-T for 15 min. Incubations with anti-c-MYC-per-
oxidase antibody (GE Healthcare, Uppsala, Sweden) were
carried out for 40 min at room temperature, followed by
membrane washing with water and TBS-T and incubation
with ECL mixture (GE Healthcare, Uppsala, Sweden) for 1
min and ECL film exposure (GE Healthcare, Uppsala,
Sweden). Films were scanned, and the band signals (opti-
cal densities) were assessed using QuantityOne software
(Bio-Rad, Hercules, CA, USA).
Protein classification
Differentially expressed proteins were classified according
to their main biological processes as well as their molecu-
lar functions using Human Protein Reference Database
(HPRD – http://www.hprd.org). Moreover, the WA differ-
entially expressed proteins were classified according their
biochemical pathways using KEGG analysis http://
www.genome.jp/kegg through software "Blast2Go" http:/
/www.blast2go.org.
Results
On average, 669 protein spots were detected in SCZ 2-DE
profiles whereas 605 protein spots were detected in CTRL
2-DE profiles (Figure 1A). There were 553 matched spots
between the groups, representing 86.8% of the average
number of spots. When individual SCZ gels and pool con-
trol gels were compared, 30 spots (~4,7%) were consist-
ently identified with significant changes in relative
abundance (> 1.4 fold difference, P < 0.05, Kruskal-Wal-
lis) (Additional file 2) [31-38]. These 30 spots revealed 25
distinct proteins with apparent altered regulation (11
downregulated and 14 upregulated in SCZ samples; Fig-
ure 1). Twenty-three proteins were identified as single
spots and two proteins were identified in multiple spots
(spots C05, C06, C07, C10 and C08, C09; Figure 1). All 25
proteins were successfully identified by MALDI-TOF/TOF
and grouped according to their biological processes and
molecular function using the Human Protein Reference
Database (HPRD – http://www.hprd.org) (Figure 2A and
Figure 2B and Additional file 2). Equivalent areas of four
distinct 2-DE gels are presented in the Figure 1D and 1E as
an example of the reproducibility of the protein profiles.
Discussion
Our findings support previous reports on altered protein
expression in SCZ as well as suggest new targets that may
be relevant for the pathobiology of this disease. The main
pathways and proteins observed are discussed bellow.
Energy metabolism dysregulation
Most proteins we identified as differentially expressed
(52%) are enzymes involved the regulation of energy
metabolism. Their altered levels can lead to an overall dis-
turbance, and ultimately contribute to the establishment
of pathological states [39,40]. In this regard, a recent
report has suggested that brain evolution from monkeys
to humans may have led to the appearance of SCZ due to
changes affecting energy pathway genes [41]. The altera-
tion of this pathway, specifically the glycolysis and gluco-
neogenesis pathways in the WA is strongly supported by
our data (Figure 2C).
Enzymes with functions in glycolysis such as ALDOC
(Aldolase C), TPI1 (Triosephosphate isomerase 1),
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase),
PGAM1 (Phosphoglycerate mutase 1) and ENO2 (Eno-
lase 2) were found to be differentially expressed in WA,
and are very likely to affect the glucose metabolism in SCZ
patients. Likewise a dysfunction in ATP metabolism can
result from differentially expressed ATP synthase subu-
nits, ATP6V1A (ATPase, H+ transporting, lysosomal 70
kDa, V1 subunit A) and ATP5A1 (ATP synthase subunit
alpha, mitochondrial). The above-mentioned proteins,
and in some cases their genes, have been previously found
to be differentially expressed in SCZ (Additional file 2).BMC Psychiatry 2009, 9:17 http://www.biomedcentral.com/1471-244X/9/17
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We also found the differential regulation of dihydropteri-
dine reductase (QDPR upregulated: 2.25×), which has
been previously found to be differentially regulated [7] in
10 SCZ patients compared to 10 paired controls. This
enzyme is a key in the control of dopamine and serotonin
synthesis [42].
In our analyses we also found two new energy-metabo-
lism-related proteins to be regulated in SCZ, which may
have important roles SCZ negative symptoms: dihydrol-
ipoyl dehydrogenase (DLD: upregulated: 2.17×) and per-
oxiredoxin 6 (PRDX6 upregulated: 2.33×). DLD is a
component enzyme of complexes such as pyruvate dehy-
drogenase, alpha-ketoglutarate dehydrogenase, and the
branched-chain alpha-keto acide dehydrogenase which
participate in cell redox processes. PRDX6 is a bifunc-
tional enzyme with two active sites with distinct roles.
This enzyme is involved in redox regulation protecting the
cell against oxidative injury by reducing levels of H2O2,
short chain organic fatty-acids and phospholipid
hydroperoxides [43]. Oxidative stress that can lead to
DNA damage, protein inactivation, altered gene expres-
sion and apoptotic events, probably starts in SCZ during
neurodevelopment. The close connection of these mecha-
nisms to neuronal plasticity suggests that an oxidative
component may be relevant to disease pathogenesis
[39,40,44]. Thus, it is plausible that the differential regu-
lation of an oxidative protector like PRDX6 may contrib-
ute to pathogenesis. The phospholipase A2 (PLA2)
activity of PRDX6 on the other hand is critical for the reg-
ulation of phospholipid turnover [43]. An accelerated
PLA2-mediated phospholipid turnover was previously
observed in SCZ frontal lobe [45] whereas an increased
activity of Ca2+-dependent PLA2 may lead to a reduced
brain dopaminergic activity [45,46]. The differential regu-
lation of PRDX6 may accelerate the phospholipid turno-
ver, leading to the described differential dopaminergic
state. As both PRDX6 activities seem to be related to SCZ
pathogenesis, we analyzed PRDX6 protein expression by
western blot (WB) in the DLPFC of SCZ patients (Figure
3A). Again, a significant differential expression of PRDX6
was found (Figure 3B). Moreover, it is interesting to note
that PRDX6 gene is localized in a chromosome loci
(1q25.1) previously related with SCZ [47].
Although a correlation between the differential expression
of glucose metabolism and oxidative phosphorylation
enzymes has been recently described in SCZ [48], there is
no consensus whether the protein expression alterations
are causes or consequences of a pathological process.
Also, the mitochondrial protein alterations found in SCZ
could be consequences of the medications used by
patients [32]. However, alterations in the glucose metab-
olism have been extensively reported as a central compo-
nent of SCZ and are unlikely due to antipsychotic effects
[41,49].
Tubulin
Tubulins are involved in multiple activities, including
mitosis, cytokinesis, and vesicular transport. Alterations
of tubulin subunits have been described in SCZ
[7,12,31,50] and were also found in WA in our study
(Additional file 2). Importantly, possible roles of tubulin
in SCZ have been suggested by Denarier et al. [51] who
generated a mouse SCZ model by knocking out the stable
tubulin-only polypeptide (STOP) gene, which is responsi-
ble for microtubule stabilization in neurons. STOP null
mice have a normal brain anatomy but show synaptic
function defects due to dysfunctional glutamatergic trans-
mission [52]. Moreover, this model exhibits a hyper-
dopaminergic state in the limbic system [53].
Representative 2-DE profile of Wernicke's area from schizo- phrenia samples is presented in A Figure 1
Representative 2-DE profile of Wernicke's area from 
schizophrenia samples is presented in A. The "S" means 
spot upregulation in SCZ and "C" spot upregulation in CTRL. 
Examples of proteins upregulated in CTRL brains are pre-
sented in the enlarged sections of the 2-DE profile (B and C). 
The reproducibility of the 2-DE profiles is demonstrated by 
the sections of four gels shown in D and E.BMC Psychiatry 2009, 9:17 http://www.biomedcentral.com/1471-244X/9/17
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Other potential markers for schizophrenia
Glial Fibrillary Acidic Protein (GFAP)
Astrocyte abnormality is a recurrent finding in SCZ.
Among other functions, astrocytes are responsible for the
maintenance of glutamatergic transmission via the gluta-
mate-glutamine cycle [54]. Glial fibrillary acidic protein
(GFAP – upregulated: 2.31×) is the major intermediate fil-
ament (IF) protein of mature astrocytes. Modifications in
the expression of this structural protein have been
reported in SCZ (Additional file 1) and can lead to com-
promised synaptic functioning and behavior alterations
[reviewed in [54]]. The over expression of GFAP, sug-
gested by our 2-DE analysis was also evaluated and con-
firmed by western-blot in individual samples of SCZ-
DLPFC (Figures 3A and 3C), reinforcing its potential role
in SCZ.
Phosphatidylethanolamine-binding protein (PEBP1)
Phosphatidylethanolamine-binding protein 1 (PEBP1 –
upregulated: 1.87×) has functions in membrane biogen-
esis and signaling mechanisms during cell growth and
maturation. PEBP1 is a calpain substrate that has been
implicated in processes that produce persistent changes in
synaptic chemistry and structure [55]. A PEBP1 knockout
mouse has been reported in 2007 [56], and revealed some
interesting associations of this protein in the control of
emotions and complex behavior responses. PEBP1 -/-
mice suffer from a decline of the smell sense and repro-
duction without any obvious fertility defects. PEBP1
appears to be upregulated in the aggression and fear con-
trolling amygdala. In a mouse model of Alzheimer's dis-
ease the loss of PEBP1 function was observed and
behavioral tests revealed a learning deficit [57].
(A) Biological processes and (B) molecular functions of differentially expressed WA proteins in SCZ Figure 2
(A) Biological processes and (B) molecular functions of differentially expressed WA proteins in SCZ. (C) KEGG 
analysis showed that some of the differentially expressed enzymes identified here (ALDOC, TPI1, GAPDH, PGAM, ENO2 and 
DLD) belongs to the same glucose-related pathway.
Differentially expressed proteins classified
by their biological processes
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Breast cancer metastasis-suppressor 1 (BRMS1)
The BRMS1 gene product seems to act as a transcriptional
regulator of diverse genes [58], and is capable to reduce
the metastatic potential of human breast cancer and
melanoma cell lines. This is the first description of the
putative alteration of BRMS1 in SCZ or any other neu-
ropsychiatric condition.
Conclusion
It is important to mention that confounding factors such
as other co-existing diseases, age, gender, or diet of the
patients or post-mortem intervals and agonal states, can sig-
nificantly impact brain proteome studies. For the particu-
lar set of samples analyzed in this study, the
electrophoretic profile of proteins from individual sam-
ples from cases and controls suggests that the post-mortem
intervals did not generate false proteome alterations in
these particular analyses (data not shown). Moreover, we
should note that all the SCZ samples used in the present
work were obtained from patients that have been treated
with antipsychotics. Distinct medications and distinct
doses or treatment regimens can certainly impact the pro-
teome studies presented here. We have calculated the false
discovery rate (FDR) of the presented dataset using the Q-
value software http://www.genomine.org/qvalue/
index.html developed by Storey 2002 [30]. FDR is a false
positive calculation method that, instead of controlling
the chance of any false positives (as Bonferroni), controls
the expected proportion of false positives. The q-value
given by FDR is the analogue of the p-value. Briefly, the q-
value is a p-value of all the p-values simultaneously. The
calculated FDR was 0.0153, suggesting that our data could
have an error of 1.53%. The validation of the differentially
expressed proteins, as we did for GFAP and PRDX6, would
be an alternative to validate the markers and to skip pos-
sible errors.
As was found for other brain regions, our data suggest an
overall energy metabolism dysregulation in WA of SCZ
patients. Beasley et al. [32] suggested that many of the
observed energy metabolism alterations could be conse-
quences of medication. On the other hand Stone et al.
[49] state that a dysfunctional energy metabolism is a cen-
tral component of SCZ and not due to an antipsychotic
effect. However, studies using samples from psychotropic
drug naïve patients will hopefully help to resolve this
issue.
Our findings are in line with a recent hypothesis of Khai-
tovich et al. [41] that states that SCZ may be a conse-
quence of human brain development. Clustered genes
that were positively selected during the evolution of the
human brain were grouped into 22 functional categories,
six of these (27,2%) included genes with functions related
to energy metabolism, some of which previously shown
to be related with SCZ. The concentration of metabolites
affected by the corresponding proteins, including lactate,
choline, and acetate were found to be different between
SCZ and control brains. It is further suggested that human
cognitive abilities are very sensitive towards alterations in
metabolite levels and even slight brain energy metabolism
dysregulations can lead to conditions that are hallmarks
of SCZ.
The consistent individual identification of altered expres-
sion levels of the same proteins derived from patient spec-
imens subjected to distinct therapeutic regimens support
a potentially important role for these biomarkers in SCZ
pathobiology. This includes PRDX6 and GFAP that were
also found in DLPFC samples. Our data add to the impor-
tance of energy metabolism pathways for SCZ and have
the potential to be translated to the clinic.
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